Suvorexant and Sleep/Delirium in ICU Patients
Key facts
- Who runs it
- Beth Israel Deaconess Medical Center
- Where
- Boston and The Bronx, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 100 people enrolled
- Started
- 28 Feb 2020
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Suvorexant 20 mg
- Placebo oral tablet
- Record updated
- 27 October 2025
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 60 years or older
- Undergoing elective coronary artery bypass graft surgery with or without aortic and/or mitral valve replacement, who are expected to be transferred to the ICU postoperatively
Who cannot take part
- Psychiatric or neurologic diseases (including chronic benzodiazepine use, bipolar disorder, psychotic disorder, posttraumatic stress disorder, requirement of prophylactic psychiatric medication, evidence of acute depression on screening visit, preexisting cognitive impairment, Alzheimer disease, Parkinson's disease, medications for cognitive decline, history of recent seizures (within 1 year prior visit), alcoholism or documented history of alcohol abuse, and narcolepsy)
- Liver failure (CHILD-Pugh>4)
- Patients with known hypersensitivity to study medications
- Preoperative left ventricular ejection fraction of less than 30%
- Renal failure (creatinine >2 mg/dl or dialysis dependence)
- Coma (RASS<-1)
- Signs and symptoms of delirium and agitation at time of enrollment (CAM-ICU positive)
- Montreal Cognitive Assessment (MoCA) below 23 at time of consent
- Severe sleep apnea requiring home continuous positive airway pressure treatment
- Morbid obesity (BMI >40)
- Known or suspected pregnancy (there are no adequate and well-controlled studies of suvorexant in pregnant women. Based on animal data, Suvorexant may cause fetal harm)
- English language limitations (Sleep assessment and delirium assessment tools are only validated in English)
- Patients enrolled in other interventional studies which could confound the primary endpoint
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Montefiore Medical Center-Albert Einstein College of MedicineThe Bronx, United States
About the trial
What the trial wants to find out
Investigators will evaluate the efficacy of postoperative oral suvorexant treatment on nighttime wakefulness after persistent sleep onset (WASO) among adult cardiac surgical patients recovering in the cardiac intensive care unit (ICU). The study include patients ≥ 60 years old undergoing coronary artery bypass graft surgery (CABG), with or without valve surgery (aortic or mitral). Patients will receive either oral suvorexant or placebo for 7 nights starting the night after extubation. The primary hypothesis is that suvorexant compared with placebo decreases WASO, as measured by a specialized electroencephalogram (EEG), the SedLine monitor, during the first night in the cardiac ICU. Investigators will also assess total sleep time (TST), time to sleep onset (TSO), and postoperative delirium and delirium-free days.
The 2 groups in the trial
- SuvorexantExisting treatment, for comparison
Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
Treatment: Suvorexant 20 mg
- PlaceboPlacebo, for comparison
Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
Treatment: Placebo oral tablet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of the Orexin Receptor Antagonist Suvorexant on Sleep Architecture and Delirium in the Intensive Care Unit: A Multi-Centric Randomized Controlled Trial
- Publications
- Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial.Critical care (London, England), 2026
- Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit.BMJ open, 2020
- Record updated
- 27 October 2025